Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?

Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?

<b>Background:</b> Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive i...

Full description

Bibliographic Details
Main Authors: Anais Romero, Charlotte Laurent, Ludivine Lebourg, Veronique Lemée, Mélanie Hanoy, Frank Le Roy, Steven Grange, Mathilde Lemoine, Dominique Guerrot, Dominique Bertrand
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Viruses
Subjects:
COVID-19
monoclonal antibodies
SARS-CoV-2
kidney transplantation
Online Access:https://www.mdpi.com/1999-4915/16/3/381

Internet

https://www.mdpi.com/1999-4915/16/3/381

Similar Items